These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes.
    Author: Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS.
    Journal: Expert Opin Pharmacother; 2008 Jul; 9(10):1705-20. PubMed ID: 18570604.
    Abstract:
    BACKGROUND: Sitagliptin is a novel agent for the treatment of type 2 diabetes either as monotherapy or in combination with metformin or a thiazolidinedione. OBJECTIVE: To review the efficacy and safety of sitagliptin in clinical trials and comment on drug interactions and safety issues arising from its use. METHODS: Relevant articles were identified through a PubMed search (up to May 2008). RESULTS/CONCLUSIONS: Sitagliptin either used alone or in combination with other hypoglycemic agents has a favorable glucose-lowering effect and safety profile. It has been associated with few side effects, mainly involving the gastrointestinal system and with a low incidence of hypoglycemia, while it generally demonstrated a neutral effect on body weight. Sitagliptin is a safe alternative or complementary option for patients with type 2 diabetes who do not reach the recommended glycosylated hemoglobin level with lifestyle interventions and/or current oral antidiabetic agents.
    [Abstract] [Full Text] [Related] [New Search]